THERAPEUTIC COMPOUNDS AND USES THEREOF
Described herein are compounds of Formula (I)-(III), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating and/or preventing diseases are also provided.
1 . A method of treating an ocular disease in an eye of a subject in need thereof, comprising injecting a compound to the eye, wherein the compound is:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is H or optionally substituted C 1-6 alkyl;
R 2 is optionally substituted bicyclic heterocyclyl having 1 or 2 heteroatoms;
X is a bond, —O—, or —C(═O)—;
Y is CH;
R 3 is optionally substituted heteroaryl; and
n is 0, 1, 2, 3, or 4.
2 . The method of claim 1 , wherein the ocular disease is a growth factor-associated disorder.
3 . The method of claim 2 , wherein the growth factor is vascular endothelial growth factor.
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . The method of claim 1 , wherein R 1 is CH 3 .
8 . The method of claim 1 , wherein R 2 is
wherein p, q, s, and t are independently 0, 1, 2, 3, or 4.
9 . The method of claim 1 , wherein X is a bond or —C(═O)—.
10 . (canceled)
11 . The method of claim 1 , wherein n is 1 or 2
12 . (canceled)
13 . The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof,
wherein:
each instance of R 4 is independently H, optionally substituted C 1-6 alkyl, F, Cl, Br, I, CN, OH, or alkoxy;
R 5 is H or a nitrogen protecting group; and
m is 0, 1, 2, 3, 4, or 5.
14 . The method of claim 13 , wherein at least one instance of R 4 is CH 3 , F, or H.
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . The method of claim 1 , wherein R 2 is
19 . (canceled)
20 . (canceled)
21 . The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
22 . A method of inhibiting growth factor signaling in a cell, comprising contacting the cell with an effective amount of a compound, wherein the compound is:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is H or optionally substituted C 1-6 alkyl;
R 2 is optionally substituted bicyclic heterocyclyl having 1 or 2 heteroatoms;
X is a bond, —O—, or —C(═O)—;
Y is CH;
R 3 is optionally substituted heteroaryl; and
n is 0, 1, 2, 3, or 4.
23 . (canceled)
24 . (canceled)
25 . (canceled)
26 . The method of claim 22 , wherein R 1 is CH 3 .
27 . The method of claim 22 , wherein R 2 is
wherein p, q, s, and t are independently 0, 1, 2, 3, or 4.
28 . The method of claim 22 , wherein X is a bond or —C(═O)—.
29 . (canceled)
30 . The method of claim 22 , wherein n is 1 or 2.
31 . (canceled)
32 . The method of claim 22 , wherein the compound is:
or a pharmaceutically acceptable salt thereof,
wherein:
R 1 is H or optionally substituted C 1-6 alkyl;
R 2 is optionally substituted bicyclic heterocyclyl having 1 or 2 heteroatoms;
X is a bond, —O—, or —C(═O)—;
each instance of R 4 is independently H, optionally substituted C 1-6 alkyl, F, Cl, Br, I, CN, OH, or alkoxy;
R 5 is H or a nitrogen protecting group;
m is 0, 1, 2, 3, 4, or 5; and
n is 0, 1, 2, 3, or 4.
33 . The method of claim 32 , wherein at least one instance of R 4 is CH 3 , F, or H.
34 . (canceled)
35 . (canceled)
36 . (canceled)
37 . The method of claim 22 , wherein R 2 is
38 . (canceled)
39 . (canceled)
40 . The method of claim 22 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
41 .- 63 . (canceled)